Market Place
Sourcing Support
Ebglyss FDA Approval Intensifies Atopic Dermatitis Competition
08 Oct 2024 //
FINANCIALXPRESS
Lilly`s Ebglyss Shows 3-Year Atopic Dermatitis Control
25 Sep 2024 //
PR NEWSWIRE
New Data Almirall`s Ebglyss Shows 3-Year Atopic Dermatitis
25 Sep 2024 //
BUSINESSWIRE
FDA Approves Lilly`s EBGLYSS For Moderate-To-Severe Atopic Dermatitis
13 Sep 2024 //
PR NEWSWIRE
NICE Recommends Ebglyss For Atopic Dermatitis In NHS England
10 Jul 2024 //
BUSINESSWIRE
Lilly`s lebrikizumab clears eczema in people with skin of color
11 Mar 2024 //
FIERCE BIOTECH
Almirall`s Ebglyss (Lebrikizumab) Receives Approval in Europe
24 Nov 2023 //
EMA
Almirall Receives European Commission Approval of EBGLYSS
17 Nov 2023 //
BUSINESSWIRE
80% of patients with atopic dermatitis maintained clear skin with lebrikizumab
20 Oct 2023 //
PR NEWSWIRE
Almirall: 80% of patients with atopic dermatitis maintained clear skin with lebrikizumab
20 Oct 2023 //
BUSINESSWIRE
Almirall`s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe AD
13 Oct 2023 //
BUSINESSWIRE
Lilly suffers another FDA snub, this time for lebrikizumab
03 Oct 2023 //
FIERCE PHARMA
EBGLYSS Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
15 Sep 2023 //
BUSINESSWIRE
Up to 73% of Atopic Dermatitis Patients Taking Lilly`s Lebrikizumab
01 May 2023 //
PR NEWSWIRE
Almirall: (NEJM) and the (BJD) Publish Ph3 Data Evaluating lebrikizumab Efficacy
31 Mar 2023 //
BUSINESSWIRE
Lilly says 4 launches will help drive 2023 revenue to $30B
14 Dec 2022 //
FIERCEPHARMA
Lebrikizumab Maintained Durable Skin Clearance in Lilly`s PIII Monotherapy Trial
08 Sep 2022 //
PRNEWSWIRE
Lilly unveils early long-term data on eczema drug
07 Jun 2022 //
ENDPTS
8 out of 10 Patients Maintained Skin Clearance at 1 Year in Lilly`s Lebrikizumab
07 Jun 2022 //
PRNEWSWIRE
Lebrikizumab + topical Corticosteroids Show Improvements in Atopic Dermatitis
11 Apr 2022 //
PRNEWSWIRE
Lilly fleshes out more PhIII data for Dupixent challenger as AD rivalry heats up
11 Apr 2022 //
ENDPTS
FDA bags snap review for Dupixent; Sanofi, Regeneron hunt 4th approval
04 Apr 2022 //
ENDPTS
Lebrikizumab Achieved Skin Clearance in Lilly`s Pivotal Phase 3 AD Studies
26 Mar 2022 //
PRNEWSWIRE
Lilly`s would-be Dupixent rival scores another late-stage win
22 Dec 2021 //
HEALIO
Lilly`s lebrikizumab hits main goals of third atopic dermatitis study
21 Dec 2021 //
PRESS RELEASE
Lebrikizumab shows skin improvement, itch relief with topical corticosteroids
21 Dec 2021 //
PRNEWSWIRE
Lilly Reports Robust Third-Quarter 2021 Financial Results
25 Oct 2021 //
PRNEWSWIRE
Eli Lilly`s Lebrikizumab Meets Main Endpoints in Atopic Dermatitis
17 Aug 2021 //
MARKET WATCH
Lilly`s lebrikizumab significantly improved skin clearance
16 Aug 2021 //
PR NEWSWIRE
Lebrikizumab shows improvements in late-stage eczema trial
16 Aug 2021 //
PHARMATIMES
Photocure announces regulatory approval of Hexvix in Chile
15 Aug 2021 //
PR NEWSWIRE
Aslan hires Kobayashi to add IL-13 clinical trial expertise
03 Aug 2020 //
FIERCE BIOTECH
Lilly and Dermira Present New Lebrikizumab Ph 2b Clinical Data Showing Patients
12 Jun 2020 //
PRESS RELEASE
Lilly Highlights the Evolution of Its Dermatology Portfolio at (AAD)
12 Jun 2020 //
PRNEWSWIRE
Lilly Announces Agreement to Acquire Dermira
11 Jan 2020 //
PR NEWSWIRE
Dermira up 29% on additional mid-stage data on dermatitis med lebrikizumab
18 Oct 2019 //
SEEKINGAPLPHA
Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients
17 Oct 2019 //
BUSINESSWIRE
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab
10 Oct 2019 //
BUSINESS WIRE
Almirall hands over $50M for European rights to Dermira`s Dupixent challenger
25 Jun 2019 //
FIERCE BIOTECH
Eyeing a $500M peak sales pot, Almirall doubles down on lebrikizumab
24 Jun 2019 //
ENDPTS
Aslan retools CSL deal, taking control of would-be Dupixent rival
03 Jun 2019 //
FIERCE BIOTECH
Little Dermira’s shares zoom up on promising PhIIb atopic dermatitis data
18 Mar 2019 //
ENDPTS
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 2018 //
PRESS RELEASE
Dermira’s 2 Ph3 Trials Evaluating Olumacostat Glasaretil Patients Acne Vulgaris
05 Mar 2018 //
PRESS RELEASE
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab
31 Jan 2018 //
PRESS RELEASE
